IR Archives - Faron

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

24.7.2026

Faron Pharmaceuticals Ltd | Company announcement | July 24, 2026 at 09:00:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer in Microsoft Word format if possible) ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ:			Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) ⁱⁱⁱ:
3. Details of person subject to the notification obligation ^iv
Name			Heights Capital Management, Inc.
City and country of registered office (if applicable)			San Francisco, California
4. Full name of shareholder(s) (if different from 3.) ^v
Name			CVI Investments, Inc.
City and country of registered office (if applicable)			Cayman Islands
5. Date on which the threshold was crossed or reached ^vi:			22/07/2026
6. Date on which issuer notified (DD/MM/YYYY):			23/07/2026
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) ^vii
Resulting situation on the date on which threshold was crossed or reached	7.99%	12.53%		20.52%	46,774,836
Position of previous notification (if applicable)	8.88%	12.53%		21.41%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached ^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ^ix					% of voting rights
		Direct (DTR5.1)		Indirect (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
		18,214,836		28,560,000			7.99%		12.53%


SUBTOTAL 8. A		46,774,836					20.52%

B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date ^x	Exercise/ Conversion Period ^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights
Convertible Bond		08/02/2027	Anytime until maturity			11,760,000			5.16%
Convertible Bond		12/02/2028	Anytime until maturity			16,800,000			7.37%

			SUBTOTAL 8. B 1			28,560,000			12.53%

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date ^x		Exercise/ Conversion Period ^xi		Physical or cash Settlement ^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) ^xiv
Name ^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc.	7.99%	12.53%	20.52%
CVI Investments, Inc.	7.99%	12.53%	20.52%




10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information ^xvi
None

Place of completion	London, United Kingdom
Date of completion	23.07.2026

Faron Provides Update on Investigator-Initiated Trial Portfolio for Bexmarilimab

13.7.2026

Faron Pharmaceuticals Ltd | Press Release | July 13, 2026 at 09:00:00 EEST

Investigators update from BLAZE in checkpoint-resistant solid tumors highlights continued progress across Faron’s expanding Investigator-Initiated Trial (IIT) portfolio

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient’s own immune system, today provides an update on its portfolio of Investigator-Initiated Trials (IITs) evaluating bexmarilimab, its wholly owned anti-Clever-1 immunotherapy, in multiple oncology indications. The update covers five IITs in solid tumors and hematological malignancies, reflecting both advances and adjustments across the program.

BLAZE: Investigators update combination treatment to approved standard-of-care nivolumab

The investigators of the BLAZE IIT, led by The Institute of Cancer Research (ICR) and conducted at The Royal Marsden NHS Foundation Trust in London, UK, as well as other leading UK hospitals, have updated the trial’s anti-PD-1 combination drug to nivolumab (Opdivo®), a fully approved, globally used standard-of-care anti-PD-1 inhibitor. The trial has received the necessary regulatory and ethical approvals and is advancing towards first patient enrolment.

The BLAZE trial is a Phase 1/2 evaluating bexmarilimab in combination with nivolumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma who have developed resistance to prior anti-PD-1-based immunotherapy. The trial investigates a sequential approach: patients first receive a run-in dose of bexmarilimab to reprogram the immunosuppressive tumor microenvironment, followed by the combination of bexmarilimab and nivolumab, with the aim of resensitizing tumors to checkpoint inhibition. Using nivolumab as the combination backbone is scientifically meaningful, because its efficacy is well characterized. Therefore, clinical activity observed in the combination treatment can be better understood.

“The current design of BLAZE allows us to generate clear and interpretable data on bexmarilimab’s ability to overcome PD-1 resistance. Nivolumab is one of the most extensively studied and used anti-PD-1 therapies in the world, and its efficacy and safety profile is well established. This provides a robust baseline against which to assess whether bexmarilimab can restore sensitivity to checkpoint inhibition in this difficult-to-treat population. We look forward to opening enrolment,” said Dr Anna Minchom, MB, BCh, FRCP, MD (res), Principal Investigator of the BLAZE trial and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust.

BEXAR: Regulatory approval received in frontline soft-tissue sarcoma

The BEXAR trial has received the necessary regulatory and ethical approvals and is advancing towards first patient recruitment. BEXAR is a randomized Phase 1b/2 IIT sponsored by MEDSIR and conducted at six Spanish hospitals and led by Dr. Cesar Serrano at the University Hospital Vall d’Hebron in Barcelona, Spain.

The trial evaluates bexmarilimab in combination with standard-of-care doxorubicin in patients with first-line metastatic soft-tissue sarcoma. The expression of bexmarilimab’s target, Clever-1, in soft-tissue sarcomas is among the highest observed across tumor types, providing a strong biological rationale for the use of bexmarilimab in this setting. Additionally, bexmarilimab’s observed effects on hematopoiesis in the bone marrow may help offset the myelosuppressive effects of doxorubicin. The trial design includes exploratory endpoints to further evaluate this hypothesis in the sarcoma setting.

“Soft-tissue sarcoma is a disease where patients desperately need new treatment options. The biology here is compelling as these tumors are rich in immunosuppressive macrophages that we believe are actively driving resistance to treatment. We are excited to begin testing whether bexmarilimab can overcome that resistance,” said César Serrano, M.D., PhD, Group Leader of the Sarcoma Translational Research Program at the Vall d’Hebron Institute of Oncology and Principal Investigator of the BEXAR trial.

FINPROVE: Bexmarilimab cohort not to proceed

The FINPROVE trial is an ongoing national, investigator‑initiated precision medicine study sponsored by Helsinki University Hospital, designed to evaluate targeted treatment approaches across multiple tumor types. Following a regulatory review by the Finnish Medicines Agency (Fimea), the proposed bexmarilimab cohort was considered incompatible with the FINPROVE platform trial, which focuses primarily on marketed therapies with established and approved patient selection strategies. This outcome does not impact Faron’s broader development program for bexmarilimab.

Forward-looking pipeline progress in hematological malignancies

Two further IITs continue to advance through active protocol development and regulatory submission preparations. The BEAM-X trial, led by the Nordic AML Group, will evaluate bexmarilimab in patients with measurable residual disease-positive acute myeloid leukemia (AML) following allogeneic stem cell transplantation. In parallel, the IIT sponsored by City of Hope National Medical Center in the United States, is planned to evaluate bexmarilimab and orally administered decitabine–cedazuridine (Inqovi®) in relapsed or refractory myelodysplastic syndromes (r/r MDS). Further updates on both IITs will be provided in due course.

About bexmarilimab

Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase 1/2 clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

For more information, please contact:

IR Partners, Finland (Media) Kare Laukkanen		+358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo		+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner		+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä		+358 (0)40 555 4727 +358 (0)50 553 8990

Faron Pharmaceuticals Ltd: Grant of Options

1.7.2026

Faron Pharmaceuticals Ltd | Company announcement | July 01, 2026 at 13:00:00 EEST

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company’s board has confirmed the grant of a total of 2,173,000 options over ordinary shares in the Company (“Options”) under the Company’s Share Option Plan 2026.

The Options have been allocated under the Share Option Plan 2026 and are exercisable after 1 June 2029, vesting 100%. The exercise price for Options allocated under the Share Option Plan is € 0.50 per share based on the resolution of the Annual General Meeting on 4 May 2026 and € 0.53 for the recipients of options who are US nationals. The terms of the Share Option Plan 2026 are available on the Company’s website.

The granted 2,173,000 Options entitle the option holders to subscribe for a total of 2,173,000 new ordinary shares in the Company, if exercised in full, and represent 0.95 % of the fully diluted ordinary share capital of the Company on the grant date.

Included in the number of Options granted are the following Options which were issued to directors and other persons discharging managerial responsibilities (“PDMRs”):

Director	Options granted

Colin Bond	60,000
Christine Roth	60,000
George Golumbeski	60,000
Juho Jalkanen	220,000
Marie-Louise Fjällskog	60,000
Tuomo Pätsi	200,000
Total directors	660,000
Other PDMR
Maija Hollmén	38,000
Vesa Karvonen	120,000
Jurriaan Dekkers	170,000
Petri Bono	170,000
Ralph Hughes	120,000
Kaisa Kyttä	100,000
Joab Wiliamson	100,000
Total other PDMRs	818,000

Total Company personnel	695,000

For more information, please contact:

IR Partners, Finland (Media) Kare Laukkanen	+358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo	+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner	+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä	+358 (0)40 555 4727 +358 (0)50 553 8990

About BEXMAB

The BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes.

About Bexmarilimab

Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	a. Colin Bond b. Christine Roth c. George Golumbeski d. Juho Jalkanen e. Marie-Louise Fjällskog f. Tuomo Pätsi g. Maija Hollmén h. Vesa Karvonen i. Jurriaan Dekkers j. Petri Bono k. Ralph Hughes l. Kaisa Kyttä m. Joab Williamson
2	Reason for notification
a.	Position/Status	Person discharging managerial responsibilities/person closely associated
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Faron Pharmaceuticals Oy
b.	LEI	7437009H31TO1DC0EB42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares ISIN: FI4000153309
b.	Nature of the transaction	Grant of options made under the Faron Share Option Plan 2026. The exercise price for Options allocated under the Share Option Plan is € 0.50 per share and € 0.53 for the recipients of options who are US nationals.
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			a. € 0.50 b. € 0.53 c. € 0.53 d. € 0.50 e. € 0.53 f. € 0.50 g. € 0.50 h. € 0.50 i. € 0.50 j. € 0.50 k. € 0.50 l. € 0.50 m. € 0.50	60,000 60,000 60,000 300,000 60,000 200,000 38,000 120,000 170,000 170,000 120,000 100,000 100,000

d.	Aggregated information – Aggregated Volume – Price	Nil
e.	Date of the transaction
f.	Place of the transaction	Turku

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

22.6.2026

Faron Pharmaceuticals Ltd | Company announcement | June 22, 2026 at 16:00:00 EEST

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA)

1. Identity of the issuer: FARON PHARMACEUTICALS OY
2. Reason for the notification (please tick the appropriate box or boxes): ☐ An acquisition or disposal of shares or voting rights ☒ An acquisition or disposal of financial instruments ☐ An event changing the breakdown of shares or voting rights ☐ Other (please specify): Click here to enter text.
3. Details of person subject to the notification obligation:
Name: Bank of America Corporation		City and country of residence: Wilmington, DE, United States of America
4. Full name of shareholder(s) (if different from 3.): –
5. Date on which the threshold was crossed or reached: 17.6.2026
6. Total positions of person(s) subject to the notification obligation:
	% of shares and voting rights (total of 7.A)		% of shares and voting rights through financial instruments (total of 7.B)	Total of both in % (7.A + 7.B)	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	0.17		8.73	8.90	227,881,315
Position of previous notification (if applicable)	0.12		9.99	10.11

7. Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
Class/type of shares ISIN code (if possible)		Number of shares and voting rights				% of shares and voting rights
		Direct (SMA 9:5)		Indirect (SMA 9:6 and 9:7)		Direct (SMA 9:5)		Indirect (SMA 9:6 and 9:7)
FI4000153309		0		377,478		0		0.17
–		–		–		–		–
–		–		–		–		–
SUBTOTAL A		377,478				0.17

B: Financial Instruments according to SMA 9:6a
Type of financial instrument	Expiration date		Exercise/ Conversion Period		Physical or cash settlement		Number of shares and voting rights		% of shares and voting rights
Rights of Use	n/a		n/a		n/a		19,584,472		8.59
swaps		15/10/2027		n/a	Cash		314,746		0.14
–	–		–		–		–		–
					SUBTOTAL B		19,899,218		8.73

8. Information in relation to the person subject to the notification obligation (please tick the applicable box): ☐ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. ☒ Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
Name	% of shares and voting rights	% of shares and voting rights through financial instruments	Total of both
Bank of America Corporation
NB Holdings Corporation
BofAML Jersey Holdings Limited
BofAML EMEA Holdings 2 Limited
ML UK Capital Holdings Limited
Merrill Lynch International
Bank of America Corporation
NB Holdings Corporation
BAC North America Holding Company
Bank of America, National Association
Bank of America Corporation
NB Holding Corporation
Bofa Securities, Inc		8.59%	8.59%

9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of Click here to enter a date.

10. Additional information: –

Done at London, United Kingdom on 18.6.2026.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

17.6.2026

Faron Pharmaceuticals Ltd | Company announcement | June 17, 2026 at 16:30:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ:			Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						x
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights						x
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights						x
Other (please specify) ⁱⁱⁱ:
3. Details of person subject to the notification obligation ^iv
Name			Timo Syrjälä
City and country of registered office (if applicable)			Monaco
4. Full name of shareholder(s) (if different from 3.) ^v
Name			Acme Investments SPF Sarl
City and country of registered office (if applicable)			Luxembourg
5. Date on which the threshold was crossed or reached ^vi:			11.6.2026
6. Date on which issuer notified (DD/MM/YYYY):			16.6.2026
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) ^vii
Resulting situation on the date on which threshold was crossed or reached	6.46%				14.712.470
Position of previous notification (if applicable)	7.77%				15.509.443

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached ^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ^ix					% of voting rights
		Direct (DTR5.1)		Indirect (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
FI4000153309		5.544.672		9.167.798			2.43%		4.02%


SUBTOTAL 8. A		14.712.470					6.46%

B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date ^x	Exercise/ Conversion Period ^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights



			SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date ^x		Exercise/ Conversion Period ^xi		Physical or cash Settlement ^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) ^xiv				X
Name ^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Timo Syrjälä (Direct)	2.43%		2.43%
Acme Investments SPF Sarl (Indirect)	4.02%		4.02%




10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information Faron has changed 11.6.2026 the way the flagging responsibility is defined by calculating also shares registered and issued to Faron and still owned by company itself. However, shares owned by Faron itself cannot be calculated as capable to vote in shareholders meetings. New total number of Faron shares registered 227.881.315.

Place of completion	Monaco
Date of completion	16.6.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

17.6.2026

Faron Pharmaceuticals Ltd | Company announcement | June 17, 2026 at 09:00:00 EEST

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA)

1. Identity of the issuer: FARON PHARMACEUTICALS OY
2. Reason for the notification (please tick the appropriate box or boxes): ☐ An acquisition or disposal of shares or voting rights ☒ An acquisition or disposal of financial instruments ☐ An event changing the breakdown of shares or voting rights ☐ Other (please specify): Click here to enter text.
3. Details of person subject to the notification obligation:
Name: Bank of America Corporation		City and country of residence: Wilmington, DE, United States of America
4. Full name of shareholder(s) (if different from 3.): –
5. Date on which the threshold was crossed or reached: 12.6.2026
6. Total positions of person(s) subject to the notification obligation:
	% of shares and voting rights (total of 7.A)		% of shares and voting rights through financial instruments (total of 7.B)	Total of both in % (7.A + 7.B)	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	0.12		9.99	10.11	206,411,888
Position of previous notification (if applicable)	0.13		10.07	10.20

7. Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
Class/type of shares ISIN code (if possible)		Number of shares and voting rights				% of shares and voting rights
		Direct (SMA 9:5)		Indirect (SMA 9:6 and 9:7)		Direct (SMA 9:5)		Indirect (SMA 9:6 and 9:7)
FI4000153309		0		246,335		0		0.12
–		–		–		–		–
–		–		–		–		–
SUBTOTAL A		246,335				0.12

B: Financial Instruments according to SMA 9:6a
Type of financial instrument	Expiration date		Exercise/ Conversion Period		Physical or cash settlement		Number of shares and voting rights		% of shares and voting rights
Rights of Use	n/a		n/a		n/a		20,374,993		9.87
Swaps		15/10/2027		n/a	Cash		245,294		0.12
–	–		–		–		–		–
					SUBTOTAL B		20,620,287		9.99

8. Information in relation to the person subject to the notification obligation (please tick the applicable box): ☐ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. ☒ Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
Name	% of shares and voting rights	% of shares and voting rights through financial instruments	Total of both
–	–	–	–
–	–	–	–
–	–	–	–
–	–	–	–
–	–	–	–

9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of Click here to enter a date.

10. Additional information:

Done at London, United Kingdom on 15.6.2026.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

15.6.2026

Faron Pharmaceuticals Ltd | Company announcement | June 15, 2026 at 18:00:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ:			Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) ⁱⁱⁱ:
3. Details of person subject to the notification obligation ^iv
Name			Heights Capital Management, Inc.
City and country of registered office (if applicable)			San Francisco, California
4. Full name of shareholder(s) (if different from 3.) ^v
Name			CVI Investments, Inc.
City and country of registered office (if applicable)			Cayman Islands
5. Date on which the threshold was crossed or reached ^vi:			11/06/2026
6. Date on which issuer notified (DD/MM/YYYY):			12/06/2026
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) ^vii
Resulting situation on the date on which threshold was crossed or reached	8.88%	12.53%		21.41%	48,784,893
Position of previous notification (if applicable)	10.33%	13.84%		24.17%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached ^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ^ix					% of voting rights
		Direct (DTR5.1)		Indirect (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
FI4000153309		20,224,893		28,560,000			8.88%		12.53%


SUBTOTAL 8. A		48,784,893					21,41%

B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date ^x	Exercise/ Conversion Period ^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights
Convertible Bond		08/02/2027	Anytime until maturity			11,760,000			5.16%
Convertible Bond		12/02/2028	Anytime until maturity			16,800,000			7.37%

			SUBTOTAL 8. B 1			28,560,000			12.53%

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date ^x		Exercise/ Conversion Period ^xi		Physical or cash Settlement ^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) ^xiv
Name ^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc.	8.88%	12.53%	21.41%
CVI Investments, Inc.	8.88%	12.53%	21.41%




10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information ^xvi
None

Place of completion	London, United Kingdom
Date of completion	12.06.2026

Faron Presents Matured BEXMAB Data at EHA 2026 Confirming Durable Efficacy and Bone Marrow Reprogramming in HR-MDS

15.6.2026

Faron Pharmaceuticals Ltd | Press Release | June 15, 2026 at 09:00:00 EEST

Data continue to demonstrate prolonged durability of response, with median duration of CR reaching 16.1 months in frontline HR‑MDS, supporting the upcoming initiation of the Phase 2b trial

Median duration of Complete Remission (CR) in treatment-naïve higher-risk myelodysplastic syndrome (HR-MDS) extended to 16.1 months with bexmarilimab + azacitidine
Frontline HR-MDS treatment achieved an 85% Overall Response Rate (ORR), with 60% of patients achieving full clearance of bone marrow blasts
Translational data indicates bexmarilimab drives bone marrow progenitor recovery and adaptive immune recruitment

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announced the poster presentation of updated translational insights and matured clinical efficacy data from its ongoing BEXMAB Phase 1/2 trial at the European Hematology Association (EHA) 2026 Congress, 11-14 June, Stockholm, Sweden. The poster highlights the steady accumulation of clinical and biological evidence validating bexmarilimab, Faron’s first-in-class immunotherapy candidate currently under clinical development for myeloid malignancies.

Enhanced remission durability and blast clearance in treatment-naïve HR-MDS

Data from the treatment-naïve HR-MDS cohort continues to mature positively, reflecting an ORR of 85% and a CR rate of 45%. Following a longer median follow-up of 14.9 months, the trial achieved substantial improvements in the durability and depth of clinical responses. Specifically, median duration of CR reached 16.1 months, indicating durable and clinically meaningful responses. Furthermore, 60% of patients now demonstrate full clearance of bone marrow blasts, a positive increase from the 55% observed in the prior data cut. As previously disclosed, Faron has achieved alignment with the FDA on the use of CR as a key endpoint for the upcoming Phase 2b trial, making the observed CR rate in this study particularly encouraging.

Dr. Mika Kontro, MD, PhD, Associate Professor at the Helsinki University Hospital Comprehensive Cancer Center and Principal Investigator of the BEXMAB trial, said, “These results reinforce the potential of bexmarilimab to deliver clinically meaningful benefit in HR-MDS. A median duration of CR of 16.1 months in frontline patients is an encouraging signal, and the translational data add important biological depth. We are seeing evidence of genuine immune reprogramming in the bone marrow, with recovery of healthy progenitor cells and activation of cytotoxic T cell responses. Together, these findings provide a compelling foundation for the randomized Phase 2b BEXERA trial.”

Pre-treatment immune status correlates with depth of clinical response

Translational analyses further demonstrated that bexmarilimab + azacitidine drives meaningful changes in the bone marrow immune landscape. Increases in basophil/mast cell and erythroid progenitor populations were observed in the majority of responding patients, alongside activation of cytotoxic CD8+ T cell responses and reductions in exhausted TIM3+ CD4+ T cells, consistent with immune reprogramming compared to azacitidine activity alone. Baseline immune profiling differentiated responders from non-responders: patients who achieved CR had a higher proportion of CD4+ and CD8+ central memory T cells and a lower proportion of terminal effector memory (TEMRA) T cells prior to treatment, suggesting a more favorable pre-existing immune context in CR responders.

“The findings presented at EHA 2026 represent a vital milestone in our disciplined generation of evidence for bexmarilimab,” said Dr. Juho Jalkanen, Chief Executive Officer of Faron. “The biological evidence of hematological recovery seen with bexmarilimab means that it reduces cancer cells and actively helps a patient’s body rebuild its blood-producing system and capacity to fight the disease, providing hope for a durable recovery where options have been historically limited.”

The safety and tolerability profile remains stable and well tolerated in this elderly, high-risk patient demographic. Backed by this clear translational validation and strong regulatory alignment, the Company is fully on track to initiate its randomized, placebo-controlled Phase 2b clinical trial (designated as the BEXERA trial) in treatment-naïve higher-risk MDS patients during the second half of 2026.

Post‑EHA webcast

Faron will host a live webcast on Monday, 15 June 2026, following the EHA Congress. The webcast will be hosted by Faron management and will feature Dr. Mika Kontro, Principal Investigator of the BEXMAB trial and presenting author of Faron’s EHA poster.

The webcast will focus on the broader clinical and scientific context of the BEXMAB programme and will include a live Q&A session.

Post‑EHA webcast registration: https://faron.videosync.fi/eha-2026

About BEXMAB

The BEXMAB trial is an open-label Phase 1/2 clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes.

About bexmarilimab

About Faron Pharmaceuticals Ltd

For more information, please contact:

IR Partners, Finland (Media) Kare Laukkanen		+358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo		+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner		+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä		+358 (0)40 555 4727 +358 (0)50 553 8990

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

11.6.2026

Faron Pharmaceuticals Ltd | Company announcement | June 11, 2026 at 17:05:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ:			Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) ⁱⁱⁱ: Issue of Treasury Shares to the Issuer						X
3. Details of person subject to the notification obligation ^iv
Name			Faron Pharmaceuticals Ltd
City and country of registered office (if applicable)			Turku, Finland
4. Full name of shareholder(s) (if different from 3.) ^v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached ^vi:			11.6.2026
6. Date on which issuer notified (DD/MM/YYYY):			11.6.2026
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) ^vii
Resulting situation on the date on which threshold was crossed or reached	25,000,000			10.97%	227,881,315
Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached ^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ^ix					% of voting rights
		Direct (DTR5.1)		Indirect (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
FI4000153309		25,000,000					10.97%


SUBTOTAL 8. A		25,000,000					10.97%

B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date ^x	Exercise/ Conversion Period ^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights



			SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date ^x		Exercise/ Conversion Period ^xi		Physical or cash Settlement ^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^xiii				x
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) ^xiv
Name ^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Faron Pharmaceuticals Ltd	10.97%		10.97%





10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information ^xvi
28.5.2026 Company announcement: Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company

Place of completion	Turku, Finland
Date of completion	11.6.2026

Faron Pharmaceuticals Ltd: Registration of Treasury Shares

11.6.2026

Faron Pharmaceuticals Ltd | Company announcement | June 11, 2026 at 17:00:00 EEST

Capitalised terms used in this announcement have the meanings given to them in the announcement made on 28 May 2026 at 15:35 EEST regarding the issue of treasury shares to the Company, unless the context provides otherwise.

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, as announced on 28 May 2026, issued 21,469,427 treasury shares to the Company itself without consideration to further prepare for any future conversions of the First and Second Tranche of Bonds.

In total, 21,469,427 new Treasury Shares in the Company have on 8 June 2026 been registered in the Finnish Trade Register. The treasury shares will rank pari passu in all respects with the existing shares of the Company. Following the registration of new Shares, the aggregate number of ordinary shares in the Company is 227,881,315 and of these shares, the Company holds 25,000,000 shares in treasury. The shares held in treasury by the Company do not confer a right to dividends or other shareholder rights.

The treasury shares will be listed on First North on 12 June 2026 and on AIM on or around 17 June 2026.

For more information, please contact:

IR Partners, Finland (Media) Kare Laukkanen	+358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo	+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner	+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä	+358 (0)40 555 4727 +358 (0)50 553 8990

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.